Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Antibiotics (Basel) ; 13(3)2024 Feb 22.
Article in English | MEDLINE | ID: mdl-38534643

ABSTRACT

Chitosan nanoparticle delivery systems have the potential for enhancing bone healing and addressing osteomyelitis. The objective was to deliver antimicrobial agents capable of preventing or treating osteomyelitis. Each formulation was optimized to achieve desired characteristics in terms of size (ranging from 100 to 400 nm), PDI (less than 0.5), zeta potential (typically negative), and in vitro release profiles for gentamicin. Entrapment percentages varied with gentamicin ranging from 10% to 65%. The chitosan nanoparticles exhibited substantial antimicrobial efficacy, particularly against P. aeruginosa and MRSA, with zones of inhibition ranging from 13 to 24 mm and a complete reduction in colony forming units observed between 3 and 24 h. These chitosan nanoparticle formulations loaded with antimicrobials hold promise for addressing orthopedic complications.

2.
Explor Res Clin Soc Pharm ; 8: 100187, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36277308

ABSTRACT

Background: The delivery of pharmaceutical care - and what that means - has been at the centre of many transformations of the pharmacy profession in the last century. Today, the exponential growth of pharmacies which provide pharmaceutical care exclusively online has placed increased scrutiny on the quality of the care they provide. Aim: As more patients are managed by remote pharmaceutical care (via medicines delivery services), we sought to critically evaluate this service to identify new research directions. Methods: The COnsolidated criteria for REporting Qualitative research and Standards for reporting qualitative research guideline provided the methodological framework throughout this process. Results: We reveal that although home delivery services ensure that many patients have access to their medicines, it may reduce time available to provide comprehensive pharmaceutical care, particularly in traditional brick-and-mortar pharmacies. Conclusion: We highlight a critical need for research in this area and suggest a variety of research directions: is remote pharmaceutical care a matter of convenience? Does remote pharmaceutical care help patients adhere to their medicines? How do digital health innovations impact care across patient demographics? What does comprehensive pharmaceutical care mean for patients?

3.
J Liposome Res ; 32(2): 181-194, 2022 Jun.
Article in English | MEDLINE | ID: mdl-34423727

ABSTRACT

In recent years, the incidence of skin cancer has increased worldwide, presenting a significant burden on healthcare services. Chemotherapy intervention is often not appropriate for all patients due to localized adverse effects on skin physiology. The aim of this study was, therefore, to consider the development of a novel phytochemical-based deformable liposomal formulation suspended in an aqueous gel for the controlled-release of naringenin. Naringenin is an antioxidant, free radical scavenger, anti-inflammatory agent, and immune system modulator thus may be potentially useful as a pharmacological anti-cancer agent. Formulated liposomes incorporating an increasing loading of Tween 20 (from 0% w/w to 10% w/w) demonstrated a significant decrease in deformability index (DI) (80.71 ± 2.02-59.17 ± 4.42 %), indicating an increase in elasticity. The release of naringenin over 24 h was directly affected by Tween-20 concentration, decreasing from 100.72%±4.98% to 79.53%±3.68% for 0% and 2% w/w Tween 20, respectively. Further, the incorporation of deformable liposomes into hydroxyethylcellulose (HEC) and hydroxypropyl methylcellulose (HPMC) gels resulting in a further retardation of naringenin release, 23.21%±1.17% and 19.83%±1.50%, respectively, over 24 h. Incubation of 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate-loaded liposomes with human dermal fibroblast (HDF) and keratinocyte cells demonstrated intracellular accumulation within 2 h, confirming deformable liposomes may be beneficial in improving drug penetration across dermal cells and would be valuable in emerging controlled-release formulations.


Subject(s)
Liposomes , Skin Absorption , Excipients , Flavanones , Humans , Polymers , Polysorbates
4.
Eur J Pharm Biopharm ; 115: 197-205, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28284728

ABSTRACT

Recent research on porous silica materials as drug carriers for amorphous and controlled drug delivery has shown promising results. However, due to contradictory literature reports on toxicity and high costs of production, it is important to explore alternative safe and inexpensive porous carriers. In this study, the potential of activated carbon (AC) as an amorphous drug carrier was investigated using paracetamol (PA) and ibuprofen (IBU) as model drugs. The solution impregnation method was used for drug loading, with loading efficiency determined by UV spectroscopy and drug release kinetics studied using USP II dissolution apparatus. The physical state of the drug in the complex was characterised using differential scanning calorimetry and X-ray diffractions techniques, whilst sites of drug adsorption were studied using Fourier transform infrared spectroscopy and N2 adsorption techniques. In addition, the cytotoxicity of AC on human colon carcinoma (Caco-2) cells was assessed using the MTT assay. Results presented here reveal that, for PA/AC and IBU/AC complexes, the saturation solubility of the drug in the loading solvent appears to have an effect on the drug loading efficiency and the physical state of the drug loaded, whilst drug release kinetics were affected by the wettability of the activated carbon particles. Furthermore, activated carbon microparticles exhibited very low cytotoxicity on Caco-2 cells at the concentrations tested (10-800µg/mL). This study, therefore, supports the potential of activated carbon as a carrier for amorphous drug delivery.


Subject(s)
Acetaminophen/chemistry , Drug Carriers/chemistry , Ibuprofen/chemistry , Adsorption , Caco-2 Cells , Calorimetry, Differential Scanning/methods , Carbon , Cell Line, Tumor , Drug Delivery Systems/methods , Drug Liberation , Humans , Microscopy, Electron, Scanning/methods , Particle Size , Porosity , Silicon Dioxide/chemistry , Solubility , Solvents/chemistry , Wettability , X-Ray Diffraction/methods
5.
Pharmaceutics ; 8(3)2016 Sep 13.
Article in English | MEDLINE | ID: mdl-27649231

ABSTRACT

Quantification of the lipid content in liposomal adjuvants for subunit vaccine formulation is of extreme importance, since this concentration impacts both efficacy and stability. In this paper, we outline a high performance liquid chromatography-evaporative light scattering detector (HPLC-ELSD) method that allows for the rapid and simultaneous quantification of lipid concentrations within liposomal systems prepared by three liposomal manufacturing techniques (lipid film hydration, high shear mixing, and microfluidics). The ELSD system was used to quantify four lipids: 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), cholesterol, dimethyldioctadecylammonium (DDA) bromide, and ᴅ-(+)-trehalose 6,6'-dibehenate (TDB). The developed method offers rapidity, high sensitivity, direct linearity, and a good consistency on the responses (R² > 0.993 for the four lipids tested). The corresponding limit of detection (LOD) and limit of quantification (LOQ) were 0.11 and 0.36 mg/mL (DMPC), 0.02 and 0.80 mg/mL (cholesterol), 0.06 and 0.20 mg/mL (DDA), and 0.05 and 0.16 mg/mL (TDB), respectively. HPLC-ELSD was shown to be a rapid and effective method for the quantification of lipids within liposome formulations without the need for lipid extraction processes.

6.
Int J Pharm ; 485(1-2): 122-30, 2015 May 15.
Article in English | MEDLINE | ID: mdl-25725309

ABSTRACT

Besides their well-described use as delivery systems for water-soluble drugs, liposomes have the ability to act as a solubilizing agent for drugs with low aqueous solubility. However, a key limitation in exploiting liposome technology is the availability of scalable, low-cost production methods for the preparation of liposomes. Here we describe a new method, using microfluidics, to prepare liposomal solubilising systems which can incorporate low solubility drugs (in this case propofol). The setup, based on a chaotic advection micromixer, showed high drug loading (41 mol%) of propofol as well as the ability to manufacture vesicles with at prescribed sizes (between 50 and 450 nm) in a high-throughput setting. Our results demonstrate the ability of merging liposome manufacturing and drug encapsulation in a single process step, leading to an overall reduced process time. These studies emphasise the flexibility and ease of applying lab-on-a-chip microfluidics for the solubilisation of poorly water-soluble drugs.


Subject(s)
Cholesterol/chemistry , Microfluidic Analytical Techniques , Phosphatidylcholines/chemistry , Propofol/chemistry , Technology, Pharmaceutical/methods , Chemistry, Pharmaceutical , Kinetics , Lab-On-A-Chip Devices , Microfluidic Analytical Techniques/instrumentation , Nanoparticles , Particle Size , Solubility , Solvents/chemistry , Technology, Pharmaceutical/instrumentation , Unilamellar Liposomes
7.
Int J Pharm ; 477(1-2): 361-8, 2014 Dec 30.
Article in English | MEDLINE | ID: mdl-25455778

ABSTRACT

Microfluidics has recently emerged as a new method of manufacturing liposomes, which allows for reproducible mixing in miliseconds on the nanoliter scale. Here we investigate microfluidics-based manufacturing of liposomes. The aim of these studies was to assess the parameters in a microfluidic process by varying the total flow rate (TFR) and the flow rate ratio (FRR) of the solvent and aqueous phases. Design of experiment and multivariate data analysis were used for increased process understanding and development of predictive and correlative models. High FRR lead to the bottom-up synthesis of liposomes, with a strong correlation with vesicle size, demonstrating the ability to in-process control liposomes size; the resulting liposome size correlated with the FRR in the microfluidics process, with liposomes of 50 nm being reproducibly manufactured. Furthermore, we demonstrate the potential of a high throughput manufacturing of liposomes using microfluidics with a four-fold increase in the volumetric flow rate, maintaining liposome characteristics. The efficacy of these liposomes was demonstrated in transfection studies and was modelled using predictive modeling. Mathematical modelling identified FRR as the key variable in the microfluidic process, with the highest impact on liposome size, polydispersity and transfection efficiency. This study demonstrates microfluidics as a robust and high-throughput method for the scalable and highly reproducible manufacture of size-controlled liposomes. Furthermore, the application of statistically based process control increases understanding and allows for the generation of a design-space for controlled particle characteristics.


Subject(s)
Liposomes , Microfluidics/methods , Microfluidics/statistics & numerical data , Technology, Pharmaceutical/methods , Technology, Pharmaceutical/statistics & numerical data , Animals , COS Cells , Chlorocebus aethiops , DNA/administration & dosage , DNA/genetics , Drug Carriers/chemistry , Fatty Acids, Monounsaturated/chemistry , High-Throughput Screening Assays , Multivariate Analysis , Particle Size , Phosphatidylethanolamines/chemistry , Quaternary Ammonium Compounds/chemistry , Transfection
8.
J Antimicrob Chemother ; 69(5): 1325-9, 2014 May.
Article in English | MEDLINE | ID: mdl-24381072

ABSTRACT

OBJECTIVES: This study measured and compared the pharmacokinetics of CMPD167, a small molecule antiretroviral CCR5 inhibitor with potential as an HIV microbicide, following vaginal, rectal and oral administration in rhesus macaques. METHODS: A vaginal hydroxyethylcellulose (HEC) gel, a rectal HEC gel, a silicone elastomer matrix-type vaginal ring and an oral solution, each containing CMPD167, were prepared and administered to rhesus macaques pretreated with Depo-Provera. CMPD167 concentrations in vaginal fluid, vaginal tissue (ring only), rectal fluid and blood plasma were quantified by HPLC-mass spectrometry. RESULTS: CMPD167 concentrations measured in rectal fluid, vaginal fluid and blood plasma were highly dependent on both the route of administration and the formulation type. Although rectal and vaginal fluid concentrations were highest when CMPD167 was administered locally (via either gel or ring), lower concentrations of the drug were also measured in these compartments following administration at the remote mucosal site or orally. CMPD167 levels in the vaginal and rectal fluid following oral administration were relatively low compared with local administration. CONCLUSIONS: The study provides clear evidence for vaginal-rectal and rectal-vaginal drug transfer pathways and suggests that oral pre-exposure prophylaxis with CMPD167 may be less efficacious at preventing sexual transmission of HIV-1 than topically applied products.


Subject(s)
Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , CCR5 Receptor Antagonists/administration & dosage , CCR5 Receptor Antagonists/pharmacokinetics , Pyrazoles/administration & dosage , Pyrazoles/pharmacokinetics , Receptors, HIV/antagonists & inhibitors , Valine/analogs & derivatives , Administration, Intravaginal , Administration, Oral , Administration, Rectal , Animals , Body Fluids/chemistry , Chromatography, High Pressure Liquid , Female , Macaca mulatta , Male , Mass Spectrometry , Valine/administration & dosage , Valine/pharmacokinetics
9.
Eur J Pharm Biopharm ; 83(1): 106-13, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23022540

ABSTRACT

Central venous catheters (CVCs) are being utilized with increasing frequency in intensive care and general medical wards. In spite of the extensive experience gained in their application, CVCs are related to the long-term risks of catheter sheath formation, infection, and thrombosis (of the catheter or vessel itself) during catheterization. Such CVC-related-complications are associated with increased morbidity, mortality, duration of hospitalization, and medical care cost [1]. The present study incorporates a novel group of Factor XIIIa (FXIIIa, plasma transglutaminase) inhibitors into a lubricious silicone elastomer in order to generate an optimized drug delivery system whereby a secondary sustained drug release profile occurs following an initial burst release for catheters and other medical devices. We propose that the incorporation of FXIIIa inhibitors into catheters, stents, and other medical implant devices would reduce the incidence of catheter sheath formation, thrombotic occlusion, and associated staphylococcal infection. This technique could be used as a local delivery system for extended release with an immediate onset of action for other poorly aqueous soluble compounds.


Subject(s)
Catheter-Related Infections/prevention & control , Dipeptides/pharmacology , Drug Delivery Systems , Factor XIIIa/antagonists & inhibitors , Sulfonamides/pharmacology , Catheters, Indwelling/adverse effects , Central Venous Catheters/adverse effects , Dipeptides/administration & dosage , Equipment and Supplies/adverse effects , Humans , Silicone Elastomers/chemistry , Sulfonamides/administration & dosage
10.
Popul Res Policy Rev ; 31(4): 545-570, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22904585

ABSTRACT

The smoking prevalence by age of women in China is distinct from most other countries in showing more frequent smoking among older women than younger. Using newly developed birth cohort histories of smoking, the authors demonstrate that although over one quarter of women born 1908-1912 smoked, levels of smoking declined across successive cohorts. This occurred despite high rates of smoking by men and the wide availability of cigarettes. The analysis shows how this pattern is counter to that predicted by the leading theoretical perspectives on the diffusion of smoking and suggests that it arose out of a mix of Confucian traditions relating to gender and the socio-economic and political events early in the 20(th) century which placed emerging women's identities in conflict with national identities. That a similar pattern of smoking is evident in Japan and Korea, two countries with strong cultural affinities to China, is used to buttress the argument.

11.
Int J Pharm ; 430(1-2): 89-97, 2012 Jul 01.
Article in English | MEDLINE | ID: mdl-22486955

ABSTRACT

A major goal in vaccine development is elimination of the 'cold chain', the transport and storage system for maintenance and distribution of the vaccine product. This is particularly pertinent to liquid formulation of vaccines. We have previously described the rod-insert vaginal ring (RiR) device, comprising an elastomeric body into which are inserted lyophilised, rod-shaped, solid drug dosage forms, and having potential for sustained mucosal delivery of biomacromolecules, such as HIV envelope protein-based vaccine candidates. Given the solid, lyophilised nature of these insert dosage forms, we hypothesised that antigen stability may be significantly increased compared with more conventional solubilised vaginal gel format. In this study, we prepared and tested vaginal ring devices fitted with lyophilised rod inserts containing the model antigen bovine serum albumin (BSA). Both the RiRs and the gels that were freeze-dried to prepare the inserts were evaluated for BSA stability using PAGE, turbidimetry, microbial load, MALDI-TOF and qualitative precipitate solubility measurements. When stored at 4 °C, but not when stored at 40 °C/75% RH, the RiR formulation offered protection against structural and conformational changes to BSA. The insert also retained matrix integrity and release characteristics. The results demonstrate that lypophilised gels can provide relative protection against degradation at lower temperatures compared to semi-solid gels. The major mechanism of degradation at 40 °C/75% RH was shown to be protein aggregation. Finally, in a preliminary study, we found that addition of trehalose to the formulation significantly reduces the rate of BSA degradation compared to the original formulation when stored at 40 °C/75% RH. Establishing the mechanism of degradation, and finding that degradation is decelerated in the presence of trehalose, will help inform further development of RiRs specifically and polymer based freeze-dried systems in general.


Subject(s)
Drug Delivery Systems/instrumentation , Serum Albumin, Bovine/chemistry , Vaccines/chemistry , Administration, Intravaginal , Chemistry, Pharmaceutical , Chromatography, High Pressure Liquid , Circular Dichroism , Delayed-Action Preparations , Drug Carriers , Drug Compounding , Drug Stability , Elastomers/chemistry , Electrophoresis, Polyacrylamide Gel , Equipment Contamination , Equipment Design , Excipients/chemistry , Female , Freeze Drying , Gels , Humans , Humidity , Hypromellose Derivatives , Methylcellulose/analogs & derivatives , Methylcellulose/chemistry , Nephelometry and Turbidimetry , Polysorbates/chemistry , Protein Conformation , Protein Stability , Serum Albumin, Bovine/administration & dosage , Solubility , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Technology, Pharmaceutical/methods , Temperature , Thermogravimetry , Time Factors , Trehalose/chemistry , Vaccines/administration & dosage
12.
Antimicrob Agents Chemother ; 56(5): 2251-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22330914

ABSTRACT

Antiretroviral entry inhibitors are now being considered as vaginally administered microbicide candidates for the prevention of the sexual transmission of human immunodeficiency virus. Previous studies testing the entry inhibitors maraviroc and CMPD167 in aqueous gel formulations showed efficacy in the macaque challenge model, although protection was highly dependent on the time period between initial gel application and subsequent challenge. In this paper, we describe the sustained release of maraviroc and CMPD167 from matrix-type silicone elastomer vaginal rings both in vitro and in vivo. Both inhibitors were released continuously during 28 days from rings in vitro at rates of 100 to 2,500 µg/day. In 28-day pharmacokinetic studies in rhesus macaques, the compounds were measured in the vaginal fluid and vaginal tissue; steady-state fluid concentrations were ~10(6)-fold greater than the 50% inhibitory concentrations (IC(50)s) for simian human immunodeficiency virus 162P3 inhibition in macaque lymphocytes in vitro. Plasma concentrations for both compounds were very low. The pretreatment of macaques with Depo-Provera (DP), which is commonly used in macaque challenge studies, was shown to significantly modify the biodistribution of the inhibitors but not the overall amount released. Vaginal fluid and tissue concentrations were significantly decreased while plasma levels increased with DP pretreatment. These observations have implications for designing macaque challenge experiments and also for ring performance during the human female menstrual cycle.


Subject(s)
CCR5 Receptor Antagonists , Cyclohexanes/pharmacokinetics , Pyrazoles/pharmacokinetics , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Immunodeficiency Virus/drug effects , Triazoles/pharmacokinetics , Valine/analogs & derivatives , Virus Internalization/drug effects , Administration, Intravaginal , Animals , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/pharmacokinetics , Biopsy , Chromatography, High Pressure Liquid , Contraceptive Devices, Female , Cyclohexanes/administration & dosage , Delayed-Action Preparations/administration & dosage , Female , HIV Infections/prevention & control , HIV-1/drug effects , HIV-1/physiology , Humans , Longitudinal Studies , Macaca mulatta , Maraviroc , Medroxyprogesterone Acetate/administration & dosage , Pyrazoles/administration & dosage , Simian Acquired Immunodeficiency Syndrome/blood , Simian Acquired Immunodeficiency Syndrome/virology , Simian Immunodeficiency Virus/physiology , Tissue Distribution , Triazoles/administration & dosage , Vagina/drug effects , Vagina/virology , Valine/administration & dosage , Valine/pharmacokinetics
13.
J Control Release ; 161(2): 389-98, 2012 Jul 20.
Article in English | MEDLINE | ID: mdl-22289435

ABSTRACT

Generally, we like to see ageing as a process that is happening to people older than ourselves. However the process of ageing impacts on a wide range of functions within the human body. Whilst many of the outcomes of ageing can now be delayed or reduced, age-related changes in cellular, molecular and physiological functionality of tissues and organs can also influence how drugs enter, distribute and are eliminated from the body. Therefore, the changing profile of barriers to drug delivery should be considered if we are to develop more age-appropriate medicines. Changes in the drug dissolution and absorption in older patients may require the formulation of oral delivery systems that offer enhanced retention at absorption sites to improve drug delivery. Alternatively, liquid and fast-melt dosage systems may address the need of patients who have difficulties in swallowing medication. Ageing-induced changes in the lung can also result in slower drug absorption, which is further compounded by disease factors, common in an ageing population, that reduce lung capacity. In terms of barriers to drug delivery to the eye, the main consideration is the tear film, which like other barriers to drug delivery, changes with normal ageing and can impact on the bioavailability of drugs delivery using eye drops and suspensions. In contrast, whilst the skin as a barrier changes with age, no significant difference in absorption of drugs from transdermal drug delivery is observed in different age groups. However, due to the age-related pharmacokinetic and pharmacodynamic changes, dose adaptation should still be considered for drug delivery across the skin. Overall it is clear that the increasing age demographic of most populations, presents new (or should that be older) barriers to effective drug delivery.


Subject(s)
Aging/physiology , Pharmacokinetics , Drug Administration Routes , Drug Delivery Systems , Humans
14.
Vaccine ; 30(17): 2778-85, 2012 Apr 05.
Article in English | MEDLINE | ID: mdl-22361120

ABSTRACT

A robust vaginal immune response is considered essential for an effective prophylactic vaccine that prevents transmission of HIV and other sexually acquired diseases. Considerable attention has recently focused on the potential of vaginally administered vaccines as a means to induce such local immunity. However, the potential for vaccination at this site remains in doubt as the vaginal mucosa is generally considered to have low immune inductive potential. In the current study, we explored for the first time the use of a quick release, freeze-dried, solid dosage system for practical vaginal administration of a protein antigen. These solid dosage forms overcome the common problem associated with leakage and poor retention of vaginally administered antigen solutions. Mice were immunized vaginally with H4A, an HIV gp41 envelope based recombinant protein, using quick release, freeze-dried solid rods, and the immune responses compared to a control group immunized via subcutaneous H4A injection. Vaginally immunized mice failed to elicit robust immune responses. Our detailed investigations, involving cytokine analysis, the stability of H4A in mouse cervicovaginal lavage, and elucidation of the state of H4A protein in the immediate-release dosage form, revealed that antigen instability in vaginal fluid, the state of the antigen in the dosage form, and the cytokine profile induced are all likely to have contributed to the observed lack of immunogenicity. These are important factors affecting vaginal immunization and provide a rational basis for explaining the typically poor and variable elicitation of immunity at this site, despite the presence of immune responsive cells within the vaginal mucosae. In future mucosal vaccine studies, a more explicit focus on antigen stability in the dosage form and the immune potential of available antigen-responsive cells is recommended.


Subject(s)
AIDS Vaccines/administration & dosage , HIV Envelope Protein gp41/immunology , HIV-1/immunology , Vagina/immunology , AIDS Vaccines/immunology , Administration, Intravaginal , Animals , Antibody Specificity/immunology , Cytokines/metabolism , Female , HIV Antibodies/immunology , HIV Infections/immunology , HIV Infections/prevention & control , Humans , Immunoglobulin A/immunology , Interleukin-2/metabolism , Mice , Mice, Inbred BALB C , Mucous Membrane/immunology , Spleen/immunology , Spleen/metabolism , Th2 Cells/immunology
15.
J Control Release ; 156(2): 161-9, 2011 Dec 10.
Article in English | MEDLINE | ID: mdl-21864598

ABSTRACT

Aqueous semi-solid polymeric gels, such as those based on hydroxyethylcellulose (HEC) and polyacrylic acid (e.g. Carbopol®), have a long history of use in vaginal drug delivery. However, despite their ubiquity, they often provide sub-optimal clinical performance, due to poor mucosal retention and limited solubility for poorly water-soluble actives. These issues are particularly pertinent for vaginal HIV microbicides, since many lead candidates are poorly water-soluble and where a major goal is the development of a coitally independent, once daily gel product. In this study, we report the use of a non-aqueous silicone elastomer gel for vaginal delivery of the HIV-1 entry inhibitor maraviroc. In vitro rheological, syringeability and retention studies demonstrated enhanced performance for silicone gels compared with a conventional aqueous HEC gel, while testing of the gels in the slug model confirmed a lack of mucosal irritancy. Pharmacokinetic studies following single dose vaginal administration of a maraviroc silicone gel in rhesus macaques showed higher and sustained MVC levels in vaginal fluid, vaginal tissue and plasma compared with a HEC gel containing the same maraviroc loading. The results demonstrate that non-aqueous silicone gels have potential as a formulation platform for coitally independent vaginal HIV microbicides.


Subject(s)
Cyclohexanes/administration & dosage , HIV Fusion Inhibitors/administration & dosage , HIV Infections/drug therapy , Silicone Elastomers/chemistry , Triazoles/administration & dosage , Vagina/metabolism , Vaginal Creams, Foams, and Jellies/chemistry , Administration, Intravaginal , Animals , Cyclohexanes/pharmacokinetics , Delayed-Action Preparations/chemistry , Female , Gels/chemistry , HIV Fusion Inhibitors/pharmacokinetics , HIV-1/drug effects , Humans , Macaca mulatta , Maraviroc , Triazoles/pharmacokinetics , Vagina/drug effects
16.
Article in English | MEDLINE | ID: mdl-21096558

ABSTRACT

Contraceptive diaphragms offer a discreet method of pregnancy protection that women can use when needed with no side effects. Incorporating antiretroviral HIV microbicides into such devices may also provide protection against HIV infection. The paper gives a brief outline of the work being conducted by PATH, CONRAD and QUB on the development of a microbicide-releasing SILCS diaphragm. The design, engineering and manufacturing challenges that have been encountered will be discussed, as well as the potential impact such a device could have in the developing world.


Subject(s)
Anti-HIV Agents/administration & dosage , Anti-Infective Agents, Local/administration & dosage , Contraceptive Devices, Female , Drug Implants/administration & dosage , HIV Infections/prevention & control , Anti-HIV Agents/chemistry , Anti-Infective Agents, Local/chemistry , Drug Implants/chemistry , Equipment Design , Equipment Failure Analysis , Female , Humans , Reproducibility of Results , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL